Authors
Latest:
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited SettingA recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
Latest:
How Does One Manage Talquetamab’s Unique AE Profile in Multiple Myeloma?Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Latest:
Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional FractionationABSTRACT Symptomatic spinal metastasis is a frequent complication of cancer that had been treated, until relatively recently, with primitive techniques to modest radiation dose levels, with a baseline assumption of limited survival and poor patient performance in that setting. In the era of targeted and personalized therapies, many patients are living longer and more functionally and are able to manage their disease on the model of chronic illness. Given these developments, an attractive option is the use of stereotactic body radiation therapy (SBRT) to deliver high biologically effective doses of radiation conformally to maximize the palliative gains of treatment. However, randomized data to guide practice are scarce. We review the extant literature and present an algorithmic approach to selecting patients with metastatic disease for palliative spinal SBRT favoring the results of available randomized studies and remaining within the safety constraints supported by evidence from randomized trials.
Latest:
A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast CancerThis study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.
Latest:
Minimally Invasive Surgery and Laparotomy Yield Similar OS in Ovarian CancerMinimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.
Latest:
Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and TherapyKhaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.
Latest:
Extreme Case of Surgical Port Metastasis in Ovarian CancerWe present the case of a 51-year-old woman with metastatic International FIGO stage IIIC ovarian cancer who had delayed her therapy after initial laparoscopy due to COVID-19 infection and presented with an extreme case of surgical port metastasis.
Latest:
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate CancerA patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
Latest:
Radiotherapy for Oligometastatic Non–Small Cell Lung Cancer: Past, Present, and FutureMcCall and Higgins examine local ablative therapy for oligometastatic NSCLC and implications for future treatment of the disease.
Latest:
Clinical Implications and Future DirectionsPanelists discuss how pembrolizumab plus lenvatinib has established a new benchmark and become the preferred first-line treatment option for more than 95% of patients with non–clear cell renal cell carcinoma (RCC), according to national guidelines, demonstrating activity across all major histological subtypes despite the heterogeneous nature of these diseases, while acknowledging that specific rare histologies may still require tailored approaches.
Latest:
Potential Solutions to Disparities in Stem Cell Transplant for Blood CancerResolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.
Latest:
Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MMThe panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
Latest:
Future of Clear Cell Renal Cell CarcinomaPanelists discuss how the future of renal cell carcinoma (RCC) treatment lies in developing better biomarkers for patient selection, novel immune therapies including chimeric antigen receptor (CAR) T cells and T-cell engagers, HIF-alpha inhibitors, radioligand therapies, and moving beyond the current immunotherapy-based doublet paradigm that has dominated for 7 years.
Latest:
The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint InhibitorsBen Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.
Latest:
Addressing Resistance to Targeted Therapies in Metastatic Colorectal CancerInvestigators discuss the use of targeted therapies to treat metastatic colorectal cancer.
Latest:
Advancing Pancreatic Cancer Care Through Intraoperative Radiation TherapyExperts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.
Latest:
Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRCThe panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
